PH12021551219A1 - Novel crystal of (3s)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1himidazol- 5-yl]-7-[5-chloro-2-(1h-tetrazol-1-yl)phenyl]-2,3- dihydroindolizin-5(1h)-one - Google Patents

Novel crystal of (3s)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1himidazol- 5-yl]-7-[5-chloro-2-(1h-tetrazol-1-yl)phenyl]-2,3- dihydroindolizin-5(1h)-one

Info

Publication number
PH12021551219A1
PH12021551219A1 PH12021551219A PH12021551219A PH12021551219A1 PH 12021551219 A1 PH12021551219 A1 PH 12021551219A1 PH 12021551219 A PH12021551219 A PH 12021551219A PH 12021551219 A PH12021551219 A PH 12021551219A PH 12021551219 A1 PH12021551219 A1 PH 12021551219A1
Authority
PH
Philippines
Prior art keywords
fluoro
chloro
phenyl
amino
dihydroindolizin
Prior art date
Application number
PH12021551219A
Other languages
English (en)
Inventor
Takayuki Fujito
Shizuka Ono
Shuhei Ohtani
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of PH12021551219A1 publication Critical patent/PH12021551219A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PH12021551219A 2018-11-30 2021-05-27 Novel crystal of (3s)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1himidazol- 5-yl]-7-[5-chloro-2-(1h-tetrazol-1-yl)phenyl]-2,3- dihydroindolizin-5(1h)-one PH12021551219A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018224434 2018-11-30
PCT/JP2019/046893 WO2020111268A1 (ja) 2018-11-30 2019-11-29 （３ｓ）－３－［２－（６－アミノ－２－フルオロピリジン－３－イル）－４－フルオロ－１ｈ－イミダゾール－５－イル］－７－［５－クロロ－２－（１ｈ－テトラゾール－１－イル）フェニル］－２，３－ジヒドロインドリジン－５（１ｈ）－オンの新規結晶

Publications (1)

Publication Number Publication Date
PH12021551219A1 true PH12021551219A1 (en) 2021-11-08

Family

ID=70853323

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021551219A PH12021551219A1 (en) 2018-11-30 2021-05-27 Novel crystal of (3s)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1himidazol- 5-yl]-7-[5-chloro-2-(1h-tetrazol-1-yl)phenyl]-2,3- dihydroindolizin-5(1h)-one

Country Status (16)

Country Link
US (1) US20210395250A1 (https=)
EP (1) EP3888653A4 (https=)
JP (1) JP7196931B2 (https=)
KR (1) KR20210097119A (https=)
CN (1) CN113226312A (https=)
AU (1) AU2019390094A1 (https=)
BR (1) BR112021010476A2 (https=)
CA (1) CA3121447A1 (https=)
IL (1) IL283481A (https=)
MX (1) MX2021006147A (https=)
NZ (1) NZ776666A (https=)
PH (1) PH12021551219A1 (https=)
SG (1) SG11202105697SA (https=)
TW (1) TWI826599B (https=)
WO (1) WO2020111268A1 (https=)
ZA (1) ZA202103692B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259143A4 (en) * 2020-12-11 2024-11-13 Board of Regents, The University of Texas System COMPOSITIONS AND METHODS FOR MANUFACTURING COCRYSTALS BY DIELECTRIC HEATING WITH DISPERSIVE AND DISTRIBUTIVE MIXTURE
JP2024125436A (ja) * 2021-07-20 2024-09-19 小野薬品工業株式会社 イミダゾール化合物の製造方法
WO2023179624A1 (zh) * 2022-03-21 2023-09-28 上海济煜医药科技有限公司 三并环类化合物制备方法及其中间体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732085B2 (en) 2011-12-21 2017-08-15 Ono Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor Xia
JP2016093285A (ja) 2014-11-13 2016-05-26 株式会社ユニバーサルエンターテインメント 遊技機
BR112017012146B1 (pt) * 2014-12-10 2023-11-21 Ono Pharmaceutical Co., Ltd Composto derivado de di-hidroindolizinona, seu uso, composição farmacêutica e inibidor de fxia
JP6992284B2 (ja) * 2016-06-06 2022-01-13 小野薬品工業株式会社 ジヒドロインドリジノン誘導体を含有する医薬組成物

Also Published As

Publication number Publication date
US20210395250A1 (en) 2021-12-23
KR20210097119A (ko) 2021-08-06
EP3888653A1 (en) 2021-10-06
IL283481A (en) 2021-07-29
ZA202103692B (en) 2023-03-29
JPWO2020111268A1 (ja) 2021-10-14
NZ776666A (en) 2024-11-29
BR112021010476A2 (pt) 2021-08-24
CN113226312A (zh) 2021-08-06
CA3121447A1 (en) 2020-06-04
WO2020111268A1 (ja) 2020-06-04
TW202039485A (zh) 2020-11-01
MX2021006147A (es) 2021-06-23
SG11202105697SA (en) 2021-06-29
AU2019390094A1 (en) 2021-06-17
JP7196931B2 (ja) 2022-12-27
EP3888653A4 (en) 2022-08-24
TWI826599B (zh) 2023-12-21

Similar Documents

Publication Publication Date Title
PH12021551219A1 (en) Novel crystal of (3s)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1himidazol- 5-yl]-7-[5-chloro-2-(1h-tetrazol-1-yl)phenyl]-2,3- dihydroindolizin-5(1h)-one
EP3990448A4 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C
SI4021901T1 (sl) Substituirane piridopirimidinonilne spojine, uporabne kot aktivatorji t-celic
PH12017500361B1 (en) Novel compounds
PH12015502705B1 (en) Processes of making and crystalline forms of a mdm2 inhibitor
UY34219A (es) Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
MY172534A (en) Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
EA201891768A1 (ru) Кристаллическая форма a агониста tlr7, ее способ получения и использование
PH12015500009A1 (en) Phenoxyethyl piperidine compounds
IL308422A (en) substituted heterocyclic compounds
EP3918845A4 (en) DISCOVERY OF IAB NODES
MX374298B (es) Método para preparar compuesto de pirrolo[3,2-d]pirimidina y sus intermediarios.
PH12014502210A1 (en) Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one
MX2016010564A (es) Procesos para preparar moduladores del canal ionico heterociclico fusionado.
ES3063350T3 (en) Novel heterocyclic compounds
IL287228A (en) A process for producing modified 2-[2-(phenyl)ethylamino]alkanamide derivatives
TN2017000065A1 (en) A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor
HK40079682A (en) Novel heterocyclic compounds
CA3278972A1 (en) Novel heterocyclic compounds
CA3262899A1 (en) NEW HETEROCYCLIC COMPOUNDS
HK40101274A (en) Substituted heterocyclic compounds
HK40101157A (en) Pyrimidine aromatic ring compounds
EP3980406A4 (en) Heterocyclic compounds
MX358421B (es) Derivados heteroaromaticos de anillo de 5 miembros que tienen actividad antagonista del receptor y5 de neuropeptido (npy).
EP3999061A4 (en) HETEROCYCLIC COMPOUNDS AS MODULATORS OF BETA-CATENIN/TCF4 INTERACTION